The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

Agentic AI refers to AI systems that add layers of reason and autonomy. They act as largely independent agents that are ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and ...

As usual, the one-two punch of ASCO and BIO set us a bit behind, but never fear – your June hires round-up is here at least ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...